266 related articles for article (PubMed ID: 37220093)
1. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
Chatur S; Vaduganathan M; Claggett B; Vardeny O; Desai AS; Jhund PS; de Boer RA; Lam CSP; Kosiborod MN; Shah SJ; Martinez F; Inzucchi SE; Hernandez AF; Haddad T; Mitter SS; Miao ZM; Petersson M; Maria Langkilde A; McMurray JJV; Solomon SD
Eur Heart J; 2023 Aug; 44(31):2930-2943. PubMed ID: 37220093
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial.
Inzucchi SE; Claggett BL; Vaduganathan M; Desai AS; Jhund PS; de Boer RA; Hernandez AF; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Verma S; Han Y; Kerr Saraiva JF; Bengtsson O; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
Lancet Diabetes Endocrinol; 2022 Dec; 10(12):869-881. PubMed ID: 36372069
[TBL] [Abstract][Full Text] [Related]
3. Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial.
Chatur S; Claggett BL; Vardeny O; Jering K; Desai AS; Pfeffer MA; Lefkowitz M; McMurray JJV; Solomon SD; Vaduganathan M
Eur J Heart Fail; 2023 Jan; 25(1):87-94. PubMed ID: 36181769
[TBL] [Abstract][Full Text] [Related]
4. Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial.
Chatur S; Vaduganathan M; Claggett BL; Cunningham JW; Docherty KF; Desai AS; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez FA; Shah SJ; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
Circulation; 2023 Nov; 148(22):1735-1745. PubMed ID: 37632455
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial.
Peikert A; Martinez FA; Vaduganathan M; Claggett BL; Kulac IJ; Desai AS; Jhund PS; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Shah SJ; Katova T; Merkely B; Vardeny O; Wilderäng U; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
Circ Heart Fail; 2022 Oct; 15(10):e010080. PubMed ID: 36029467
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial.
Ostrominski JW; Vaduganathan M; Selvaraj S; Claggett BL; Miao ZM; Desai AS; Jhund PS; Kosiborod MN; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Petersson M; Maria Langkilde A; McMurray JJV; Solomon SD
Circulation; 2023 Dec; 148(24):1945-1957. PubMed ID: 37830208
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.
Kondo T; Butt JH; Curtain JP; Jhund PS; Docherty KF; Claggett BL; Vaduganathan M; Bachus E; Hernandez AF; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Kosiborod MN; Desai AS; Køber L; Ponikowski P; Sabatine MS; Solomon SD; McMurray JJV
Circ Heart Fail; 2023 Dec; 16(12):e010898. PubMed ID: 37886880
[TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status.
Peikert A; Goyal P; Vaduganathan M; Claggett BL; Kulac IJ; Miao ZM; Vardeny O; Kosiborod MN; Desai AS; Jhund PS; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
JACC Heart Fail; 2023 Oct; 11(10):1380-1393. PubMed ID: 37294244
[TBL] [Abstract][Full Text] [Related]
9. Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
Jackson AM; Dewan P; Anand IS; Bělohlávek J; Bengtsson O; de Boer RA; Böhm M; Boulton DW; Chopra VK; DeMets DL; Docherty KF; Dukát A; Greasley PJ; Howlett JG; Inzucchi SE; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Ljungman CEA; Martinez FA; O'Meara E; Sabatine MS; Sjöstrand M; Solomon SD; Tereshchenko S; Verma S; Jhund PS; McMurray JJV
Circulation; 2020 Sep; 142(11):1040-1054. PubMed ID: 32673497
[TBL] [Abstract][Full Text] [Related]
10. Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
Vaduganathan M; Claggett BL; Jhund P; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Hegde SM; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
JAMA Cardiol; 2022 Dec; 7(12):1259-1263. PubMed ID: 36190011
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial.
Mc Causland FR; Claggett BL; Vaduganathan M; Desai AS; Jhund P; de Boer RA; Docherty K; Fang J; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Saraiva JFK; McGrath MM; Shah SJ; Verma S; Langkilde AM; Petersson M; McMurray JJV; Solomon SD
JAMA Cardiol; 2023 Jan; 8(1):56-65. PubMed ID: 36326604
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Solomon SD; McMurray JJV; Claggett B; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Jhund PS; Belohlavek J; Chiang CE; Borleffs CJW; Comin-Colet J; Dobreanu D; Drozdz J; Fang JC; Alcocer-Gamba MA; Al Habeeb W; Han Y; Cabrera Honorio JW; Janssens SP; Katova T; Kitakaze M; Merkely B; O'Meara E; Saraiva JFK; Tereshchenko SN; Thierer J; Vaduganathan M; Vardeny O; Verma S; Pham VN; Wilderäng U; Zaozerska N; Bachus E; Lindholm D; Petersson M; Langkilde AM;
N Engl J Med; 2022 Sep; 387(12):1089-1098. PubMed ID: 36027570
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial.
Butler J; Usman MS; Filippatos G; Ferreira JP; Böhm M; Brueckmann M; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Senni M; Sumin M; Verma S; Zaremba-Pechmann L; Pocock SJ; Packer M; Anker S
JAMA Cardiol; 2023 Jul; 8(7):640-649. PubMed ID: 37223933
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction.
Cunningham JW; Vaduganathan M; Claggett BL; Kulac IJ; Desai AS; Jhund PS; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; McGrath MM; O'Meara E; Wilderäng U; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2022 Oct; 80(14):1302-1310. PubMed ID: 36041912
[TBL] [Abstract][Full Text] [Related]
15. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial.
Peikert A; Bart BA; Vaduganathan M; Claggett BL; Kulac IJ; Kosiborod MN; Desai AS; Jhund PS; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Petersson M; Langkilde AM; McMurray JJV; Solomon SD; Vardeny O
JACC Heart Fail; 2024 Apr; 12(4):631-644. PubMed ID: 37767674
[TBL] [Abstract][Full Text] [Related]
16. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER.
Wang X; Vaduganathan M; Claggett BL; Hegde SM; Pabon M; Kulac IJ; Vardeny O; O'Meara E; Zieroth S; Katova T; McGrath MM; Pouleur AC; Jhund PS; Desai AS; Inzucchi SE; Kosiborod MN; de Boer RA; Kober L; Sabatine MS; Martinez FA; Ponikowski P; Shah SJ; Hernandez AF; Langkilde AM; McMurray JJV; Solomon SD; Lam CSP
Circulation; 2023 Feb; 147(8):624-634. PubMed ID: 36342789
[TBL] [Abstract][Full Text] [Related]
17. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
Mc Causland FR; Claggett BL; Vaduganathan M; Desai A; Jhund P; Vardeny O; Fang JC; de Boer RA; Docherty KF; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Saraiva JFK; McGrath MM; Shah SJ; Verma S; Langkilde AM; Petersson M; McMurray JJV; Solomon SD
JAMA Cardiol; 2024 Feb; 9(2):144-152. PubMed ID: 37952176
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum.
Butt JH; Docherty KF; Claggett BL; Desai AS; Fang JC; Petersson M; Langkilde AM; de Boer RA; Cabrera Honorio JW; Hernandez AF; Inzucchi SE; Kosiborod MN; Køber L; Lam CSP; Martinez FA; Ponikowski P; Sabatine MS; Vardeny O; O'Meara E; Saraiva JFK; Shah SJ; Vaduganathan M; Jhund PS; Solomon SD; McMurray JJV
JACC Heart Fail; 2023 Apr; 11(4):375-388. PubMed ID: 36881399
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics.
Yeoh SE; Osmanska J; Petrie MC; Brooksbank KJM; Clark AL; Docherty KF; Foley PWX; Guha K; Halliday CA; Jhund PS; Kalra PR; McKinley G; Lang NN; Lee MMY; McConnachie A; McDermott JJ; Platz E; Sartipy P; Seed A; Stanley B; Weir RAP; Welsh P; McMurray JJV; Campbell RT
Eur Heart J; 2023 Aug; 44(31):2966-2977. PubMed ID: 37210742
[TBL] [Abstract][Full Text] [Related]
20. Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER.
Butt JH; Lu H; Kondo T; Bachus E; de Boer RA; Inzucchi SE; Jhund PS; Kosiborod MN; Lam CSP; Martinez FA; Vaduganathan M; Solomon SD; McMurray JJV
Eur J Heart Fail; 2023 Nov; 25(11):2078-2090. PubMed ID: 37634087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
